What is the role of sotorasib in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Sotorasib is indicated for KRAS G12C–mutated locally advanced or metastatic NSCLC in adults who have received 1 or more prior systemic therapies. Sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS. 

Accelerated approval was supported by the CodeBreak 100 phase 2 trial. In 124 patients who had measurable disease at baseline were evaluated. An objective response was observed in 46 patients (37.1%), including 4 who had a complete response and 42 with partial response. Disease control occurred in 100 patients (80.6%) and median overall survival was 12.5%. [170]  

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!